Introduction
Glatiramer acetate (GA, copolymer 1, Copaxoneâ) is a heterogeneous but standardized mixture of synthetic polypeptides consisting of L-glutamic acid, L-lysine, L-alanine and L-tyrosine (average molecular mass, 6400 Da). GA has been known for a long time to have suppressive and protective effects in experimental autoimmune encephalomyelitis, which can be induced in different species by various encephalitogenic antigens (Teitelbaum et al., 1972; Webb et al., 1975; Teitelbaum et al., 1996; Sela, 1999) . More recently, GA has also been shown to have bene®cial effects on the clinical course and MRI-de®ned brain lesions of patients with multiple sclerosis. As a result, GA is now approved for use in the immunomodulatory therapy of relapsing-remitting multiple sclerosis (Teitelbaum et al., 1997; Comi et al., 2001; Sela et al., 2001; Ziemssen et al., 2001) Among potential mechanisms, the initial T-helper 1 (TH1) type response of GA-treated patients was found to gradually shift to a T-helper 2 (TH2) type response (Miller et al., 1998; Duda et al., 2000; Gran et al., 2000; Neuhaus et al., 2000; Qin et al., 2000) . TH1 cells characteristically produce a spectrum of`proin¯ammatory' cytokines such as interferon (IFN)-g, interleukin (IL)-2 and IL-12. In contrast, TH2 cells produce TH2-type`anti-in¯ammatory' cytokines, i.e. IL-4, IL-5, IL-6 and IL-13 (Paul and Seder, 1994; Mosmann and Sad, 1996; Allen and Maizels, 1997 ). An intermediate type of T cell, called a TH0 cell, produces both TH1-and TH2-type cytokines. Current theories propose that the GA-speci®c TH2 cells, which are induced and constantly activated during treatment, migrate into the CNS and release their TH2-like cytokines locally (Aharoni et al., 2000) . These cytokines are thought to have bene®cial effects on the local in¯ammatory milieu and to inhibit the action of encephalitogenic T cells bỳ bystander suppression' .
Although plausible, this scenario may actually be an oversimpli®cation as two unexpected and intriguing ®ndings suggest. Human immune cells including T-lymphocytes, B-lymphocytes and monocytes can produce brain-derived neurotrophic factor (BDNF) (Besser and Wank, 1999; Kerschensteiner et al., 1999) Ða potent neurotrophin that has profound effects on neuronal survival and repair (Thoenen, 1995; Barde, 1997) . Moreover, the receptor for BDNF, gp145TrkB, is expressed in neurones and astrocytes in multiple sclerosis brain lesions (Stadelmann et al., 2002) . These ®ndings prompted us to ask the following questions: (i) can GA-reactive T lymphocytes produce BDNF, and if so, (ii) do TH1-type and TH2-type GA-speci®c T cells differ in their capacity to produce BDNF?
To answer these questions, we ®rst had to overcome two major technical obstacles: (i) adapting our culture system to prevent added GA from affecting the BDNF enzyme-linked immunosorbent assay (ELISA) and (ii) optimizing the intracellular detection of BDNF in individual T-lymphocytes. This enabled us to demonstrate formally that GA-speci®c TH1, TH2 and TH0 cells all have the capacity to produce BDNF. We therefore postulate that the bene®cial effects of not only TH2-type, but also TH1-type GA-reactive T cells, might, at least partly, be due to their release of BDNF in multiple sclerosis lesions.
Material and methods Subjects
Blood samples were drawn from a GA-treated patient (B.K.) and a healthy donor (T.Z.) after their informed consent was given. The patient, a 47-year-old woman, had been diagnosed in 1993 to have relapsing-remitting multiple sclerosis. Her current Expanded Disability Status Scale (EDSS) (Kurtzke, 1983 ) is 1. She has been essentially free of exacerbations since GA treatment was started in December 1998. Her human leukocyte antigen (HLA) class II phenotype is DR2/ DR4. The HLA class II phenotype of the healthy volunteer (T.Z.), a 28-year-old postdoctoral fellow, is DR8/DR13. HLA typing was kindly performed by Drs E. Albert and S. Scholz, Department of Immunogenetics, University of Munich, Germany.
Selection and culture of GA-speci®c T-cell lines (TCLs)
GA-speci®c CD4+ TCLs were selected from peripheral blood mononuclear cells (PBMCs) using a split-well technique (Kitze et al., 1988; Pette et al., 1990; Neuhaus et al., 2000) . GA (batch 242992899, average molecular mass 6400 Da) was obtained from Teva Pharmaceutical Industries, Petah Tiqva, Israel.
Four GA-speci®c CD4+ TCL representatives of the phenotypes TH1 (TZ-COP-1), TH1/0 (TZ-COP-3), TH0 (TZ-COP-5) and TH2 (BK-M6-COP-7) were used (Neuhaus et al., 2000) . The protocols for¯uorescence-activated cell sorter (FACS) phenotyping of the TCLs are described below. The TCLs TZ-COP-1, TZ-COP-3 and TZ-COP-5 were obtained from the healthy untreated subject T.Z. The TH2-type TCL, BK-M6-COP-7, was obtained from the GA-treated patient B.K. This TCL was originally described by Neuhaus et al. (2000) .
Stimulation of GA-speci®c TCL with GA-pulsed antigen presenting cells (APCs)
In pilot experiments, the GA in the culture supernatants was occasionally observed to interfere with the BDNF ELISA, especially in the low range of BDNF concentrations (M. Kerschensteiner, W. Klinkert and T. Ziemssen, unpublished data) . We therefore established a rigorous antigenpulsing protocol to minimize these soluble GA concentrations. This protocol was used in all the experiments reported here. Thrombocyte-depleted APCs, X-irradiated with 40 Gy (Stabiloplan 2; Siemens, Erlangen, Germany), were incubated (`pulsed') with GA at a ®nal concentration of 400 mg/ml for 4 h. The GA-pulsed APCs were washed twice before being used to stimulate the GA-speci®c TCLs. The same protocol was used for parallel proliferation assays. Proliferation was measured by [ 3 H]thymidine uptake as described previously (Neuhaus et al., 2000) .
For proliferation and BDNF secretion (ELISA) assays, 10 5 washed GA-speci®c TCL cells were stimulated in RPMI 1640 medium supplemented with 5% foetal calf serum (FCS), 1% glutamine and 1% penicillin/streptomycin (all from Gibco BRL, Gaithersburg, MD, USA) with 9 Q 10 4 GA-pulsed . The T-cell receptor (TCR) Vb (variable region) repertoire was analysed using monoclonal antibodies that recognize the following subfamilies: Vb2, Vb3, Vb3.1, Vb5.3, Vb7, Vb7.1, Vb8, Vb9, Vb11, Vb12, Vb13.1, Vb13.2, Vb13.6, Vb14, Vb17, Vb18, Vb20, Vb21.3, Vb23 (Immunotech) and Vb5a, Vb5b, Vb6.7 (T-cell Diagnostics, Woburn, MA, USA). Monoclonal antibodies and isotype controls [mouse IgG1 (Becton Dickinson); mouse IgG2a and IgG2b (Cymbus, Chandlers Ford, Hampshire, UK)] were visualized with a FITC-labelled goat anti-mouse IgG antibody (Jackson ImmunoResearch, West Grove, PA, USA). The stained cells were analysed using a FACScan (Becton Dickinson).
Intracellular¯ow cytometry analysis of cytokine pro®le and BDNF production
Intracellular¯ow cytometry of the TCLs was performed 8± 10 days after restimulation in the absence of viable APCs. GA-speci®c TCL were stimulated with phorbol 12-myristate 13-acetate (PMA, 2.0 mg/ml) and ionomycin (250 pg/ml) (both from Sigma, St Louis, MO, USA) for 3 h (cytokine pro®le) or 12 h (BDNF production); the last 2 h (cytokine pro®le) or 6 h (BDNF production) in the presence of monensin (2 mmol/l; Sigma). The T cells were then washed with phosphate-buffered saline (PBS) ®xed with 4% paraformaldehyde (Merck, Darmstadt, Germany) and permeabilized with 0.1% saponin/PBS (Sigma). For the characterization of the cytokine pro®le, the T cells were then stained using appropriate concentrations of monoclonal antibody directed against IL-4 (mouse IgG1, PE-labelled; PharMingen) and IFN-g (mouse IgG1, FITC-labelled; PharMingen) or the corresponding isotype controls [mouse IgG1, PE-labelled (Becton Dickinson); mouse IgG1, FITClabelled (Immunotech)]. For the detection of intracellular BDNF production, activated and non-activated T cells were stained with a chicken IgY antibody against human BDNF or, as an isotype control, with a chicken control immunoglobulin IgY (both Promega, Madison, WI, USA). IgY, the 180 kDa chicken IgG homologue, can be produced in chickens against certain biological antigens that fail to elicit a humoral immune response in other mammals due to species relatedness. The antibody is highly speci®c for BDNF. A rabbit antichicken Ig antibody (FITC-labelled; Promega) was used as secondary antibody.
The untransfected murine ecotropic packaging line GP+E86 was used as a negative control for intracellular BDNF FACS staining. The packaging line transfected with the retroviral vector pLXSN into which BDNF cDNA was cloned (kindly provided by R. Kramer, Max-Planck-Institute of Neurobiology, Martinsried, Germany) served as a positive control (Flugel et al., 2001) .
The stained cells were analysed using a FACScan (Becton Dickinson). On a dot plot showing forward and side scatter, lymphoid cells were gated for further analysis. Dead cells were excluded by gating.
Quanti®cation of BDNF protein secretion in culture supernatants by ELISA BDNF protein concentrations were determined in duplicate using a sensitive sandwich ELISA as described previously (Kerschensteiner et al., 1999) . In brief, 96-well at-bottomed plates were coated with the chicken anti-human BDNF IgY antibody (Promega) in 0.025M NaHCO 3 and 0.025M Na 2 CO 3 (pH 8.2). Recombinant human BDNF (used as standard; Research Diagnostics, Flanders, PA, USA) was used in serial dilutions and cell supernatants in 1 : 2 dilutions. Bound BDNF was detected by incubating plates with a mouse anti-human BDNF antibody (Research Diagnostics) followed by peroxidase-conjugated goat antimouse IgG (Dianova, Hamburg, Germany). The plates were developed using a 3,3¢,5,5¢-tetramethyl-benzidine liquid substrate system (Sigma); the optical density was determined at 450 nm.
RT-PCR analysis of BDNF transcription
Total cellular RNA was extracted using the RNA extraction system of Qiagen (Hilden, Germany) with DNase digestion. The RNA (1 mg) was transcribed with oligo(dt) primers, Superscriptâ Reverse Transcriptase (both Gibco BRL) and dNTP (MBI Fermentas, St Leon-Rot, Germany). All PCR reactions were carried out in a total volume of 50 ml containing 2 U Taq polymerase (Qiagen), 200 mM of each dNTP, and 15 pmol of each primer for 35 PCR cycles with an annealing temperature of 60°C. The correct size of the bands was determined by comparison with a DNA mass standard (SM0403, MBI Fermentas). RNA samples incubated in the absence of reverse transcriptase were used as negative controls to exclude genomic contamination. The primer sequences were as follows: BDNF forward 5¢-AGCGTG-AATGGGCCCAAGGCA-3¢ (position 208±228); BDNF reverse 5¢-TGTGACCGTCCCGCCCGACA-3¢ (position 570±551); b-actin forward 5¢-CCTCGCCTTTGCCGA-TCC-3¢ (position ±8 to 9); and b-actin reverse 5¢-GGATCT-TCATGAGGTAGTCAGTC-3¢ (position 623±604).
Results

Phenotypic characterization of GA-speci®c TCLs
To analyse the production of BDNF by GA-speci®c T cells after antigen challenge in vitro, four GA-speci®c long-term TCLs were usedÐone TCL obtained from the GA-treated multiple sclerosis patient (B.K.) and three TCLs from the healthy donor (T.Z.). The TCLs were selected with the splitwell cloning technique (Kitze et al., 1988; Pette et al., 1990) . FACS analysis showed that all GA-speci®c TCLs had a CD3 + CD4 + CD8 ± phenotype (data not shown). The TCL from the multiple sclerosis patient (BK-M6-COP-7) was previously characterized as part of another study (Neuhaus et al., 2000) . The other three TCLs were analysed as to their TCR Vb usage. A panel of 23 different anti-TCR-Vb antibodies was used to demonstrate the oligoclonal nature of the TCLs. As characteristically seen with TCLs selected with the splitwell protocol (Kitze et al., 1988; Pette et al., 1990) , each line reacted predominantly with one monoclonal antibody from the panel of anti-TCR Vb antibodies (Fig. 1) . The three investigated TCLs used different Vb elements. The fact that the TCL populations predominantly stained positive for only one of the 23 Vb elements indicated that they were oligoclonal (Fig. 1) . Fig. 1 shows the cytokine pro®le of the TCLs for IL-4 and IFN-g. Whereas the TCLs TZ-COP-1 and TZ-COP-3 displayed a TH1 or TH1/TH0 phenotype, TZ-COP-5 cells produced both IL-4 and IFN-g (TH0 phenotype). As described previously (Neuhaus et al., 2000) , the TCL from the GA-treated multiple sclerosis patient (BK-M6-COP-7) had a stable TH2 cytokine pro®le (Fig. 1) .
GA-induced proliferation and BDNF protein secretion by GA-speci®c TCLs
To demonstrate the ability of GA-speci®c T cells to secrete BDNF upon stimulation, we quanti®ed the amount of BDNF in supernatants of GA-stimulated T cells and, in parallel, assessed the proliferative response to GA (Fig. 2) . All GAspeci®c TCLs showed a speci®c proliferative response to GA with stimulation indices ranging between 6.5 and 21.0 over several re-stimulations. None of the tested GA-speci®c TCLs showed a proliferative response or cytokine production when challenged with myelin basic protein (MBP) as was previously reported for murine and human GA-speci®c T cells (data not shown) (Aharoni et al., 1998; Neuhaus et al., 2000) . Irradiated APCs alone did not proliferate, regardless of whether they were pulsed with GA or not (Fig. 2) . When T cells were added to unpulsed APCs, there was a small background proliferation that was at least six times lower than the proliferation in the presence of GA-pulsed APCs (Fig. 2,  right columns) .
The results of the BDNF ELISA indicate that the irradiated APCs (that is, PBMCs containing monocytes, T cells and B cells) produced small but clearly detectable amounts of BDNF (Fig. 2 , left columns in left panels), although they did not proliferate (Fig. 2 , left columns in right panels). There was a tendency for higher BDNF production by GA-pulsed APCs alone. All GA-speci®c TCLs showed an increased BDNF production after incubation with GA-pulsed APCs (Fig. 2 , right columns in left panels).
RT-PCR analysis of BDNF transcription in GA-speci®c TCL
The transcription of BDNF mRNA in GA-speci®c T-cells was analysed by RT-PCR. In contrast to the BDNF protein secretion assay, the cells were harvested after a culture period of 24 h for RNA extraction and reverse transcription. The expression of BDNF was examined using RT-PCR in comparison with the housekeeping gene b-actin. There was no detectable contamination by genomic DNA, i.e. there were no bands in the negative BDNF and b-actin controls using RNA samples processed in the absence of reverse transcriptase (Fig. 3) . Consistent with the BDNF protein data shown in Fig. 2 , RT-PCR revealed weak bands in the absence of GA and stronger bands in the presence of GA (Fig. 3) .
Detection of BDNF protein in GA-speci®c T-cells by intracellular¯ow cytometry
To con®rm that the GA-speci®c T-cells are the source of the GA-induced BDNF release, we developed a new intracellular staining technique suitable for¯ow cytometry and FACS analysis of intracellular BDNF production. This method allows the analysis of BDNF production by individual unstimulated und stimulated T cells. Since the analysis was performed at least 8±10 days after the last restimulation with antigen and irradiated APCs, the cultures contained only T cells in the absence of viable APCs. Before intracellular staining and FACS analysis, the T cells were stimulated with ionomycin and PMA; this mode of stimulation does not require the presence of APCs (Dayton et al., 1994) . A BDNFtransfected and non-transfected murine retroviral packaging line was used as the positive and negative controls (Fig. 4 , top panels).
This new method was able to detect BDNF produced by the GA-speci®c TCLs, even without stimulation (left panels in Fig. 4 ; ®ne lines represent isotype controls). After stimulation with ionomycin and PMA, there was an increase of intracellular BDNF production (Fig. 4, right panels) . The results of this intracellular assay of BDNF expression are consistent with the results of the ELISA and RT-PCR analysis.
Discussion
Technical aspects of the study
We clearly show that GA-speci®c, activated TH0, TH1 and TH2 cells produce the neurotrophic factor BDNFÐnot only at the transcriptional (mRNA) level by RT-PCR, but also at the protein levelÐusing the newly developed assays for Fig. 1 Phenotypical characterization of the GA-speci®c TCLs (TZ-COP-1, TZ COP-3, TZ-COP-5, BK-M6-COP-7) as to their Vb TCR usage (left panels: ®ne lines represent isotype controls and bold lines represent the indicated TCR Vb antibodies) and their cytokine secretion pro®le analysed by intracellular double-¯uorescence cytometry (middle panels with isotype controls; right panels with the cytokine pro®le). ND* = not done; the Vb TCR usage of the published GA-speci®c T cell line BK-M6-COP-7 was not determined (Neuhaus et al., 2000) . Fig. 2 BDNF secretion (left panels) and proliferation (right panels) of the examined GA-speci®c TCLs (TZ-COP-1, TZ-COP-3, TZ-COP-5, BK-M6-COP-7) after restimulation with GA. Irradiated autologous unpulsed and GA-pulsed APCs were analysed alone and in coculture with the examined TCL as described in Material and methods. Filled columns indicate mean of duplicates and vertical lines indicate individual measurements. Different ordinate scales are used. The statistical signi®cance of the difference between BDNF production of (unpulsed APC+TCL) versus (GA-pulsed APC+TCL) was P < 0.0003 (t-test; all TCL included).
BDNF secretion and synthesis of BDNF in individual T cells.
The results from all assays consistently showed a low level of basal secretion of BDNF by GA-speci®c T cells and an increase of BDNF production after stimulation. For our analysis, we selected four well-characterized prototypic GAspeci®c TCLs. Similar results were obtained with >20 additional GA-speci®c TCLs (data not shown).
In pilot experiments, the presence of soluble GA in culture supernatants sometimes caused elevated ELISA readings for BDNF (M. Kerschensteiner, W. Klinkert and T. Ziemssen, unpublished data). To prevent that, we pre-pulsed the APCs with GA and washed them, before co-culturing with our highly puri®ed long-term GA-speci®c oligoclonal TCL. In this culture system, the irradiated PBMC produced small amounts of BDNF even in the absence of GA-speci®c TCLs (Fig. 2) . This was expected because the irradiated PBMC preparations contained T cells, and GA strongly stimulates T cells from naõ Ève human subjects (Duda et al., 2000a; Duda et al., 2000b; Farina et al., 2001) . Although proliferation of the irradiated PBMC was abolished completely, some GAstimulated BDNF production evidently persists (Fig. 2) . When the GA-speci®c TCLs were added, BDNF production increased and was highest in the presence of GA-pulsed APCs. Qualitatively similar results were obtained in the parallel proliferation assays. All four tested TCLs yielded consistent results in all assays (Fig. 2) .
To show conclusively that the BDNF is produced by the GA-speci®c T cells rather than the APCs, we optimized its detection in individual T cells in the absence of APCs. Similar assays are widely used for the intracellular staining of various cytokines, including IL-4 and IFN-g (see Fig. 1) ; the T cells are typically stimulated with ionomycin and PMA [an antigen-independent maximal stimulus for T cells (Dayton et al., 1994) ] before being ®xed and permeabilized. In preliminary experiments with a series of monoclonal and polyclonal antibodies to BDNF, we obtained the best results with a highly speci®c chicken anti-human BDNF antiserum (Fig. 4) that also detects BDNF in ELISA and speci®cally labels a murine retroviral packaging cell line transfected with BDNF-cDNA. Together with the results of RT-PCR and ELISA, these results formally establish that human GAspeci®c T cells of different TH types can indeed produce BDNF.
Implications for the presumed mechanism of action of GA Our ®ndings have obvious implications for the presumed mechanism of action of GA. According to current theory, the bene®cial effects of GA are mainly mediated by a population of GA-reactive TH2 cells. GA treatment induces a gradual shift of GA-reactive T cells from TH1 to TH2 (Miller et al., 1998; Neuhaus et al., 2000; Duda et al., 2000a; Farina et al., 2001) . Their constant activation by daily immunization enables them to enter the CNS (Wekerle et al., 1986; Hickey et al., 1999) . Indeed, transferred GA-reactive T cells have been directly demonstrated in the CNS of recipient mice (Aharoni et al., 2000) . It is further assumed, that after local recognition of cross-reactive myelin degradation products, the GA-speci®c TH2 cells are stimulated to secrete antiin¯ammatory cytokines, which in turn induce bystander suppression in neighbouring encephalitogenic T cells (Aharoni et al., 1997; Aharoni et al., 1998; Neuhaus et al., 2001) . Our present ®ndings imply that the locally activated GA-reactive TH2 cells produce not only protective TH2 cytokines, but also BDNF. They further indicate that GAspeci®c TH1 cells, which are reduced but are still present in GA-treated patients (Neuhaus et al., 2000; Farina et al., 2001) , could also act as a local source of BDNF.
BDNF is one of the most potent factors supporting neuronal survival and regulating neurotransmitter release and dendritic growth (Thoenen, 1995; Lewin and Barde, 1996; Barde, 1997) . Several studies have shown that BDNF can rescue injured or degenerating neurones and induce axonal outgrowth, remyelination and regeneration (Yan et al., 1992; Gravel et al., 1997) . Moreover, it can also protect axons from elimination during development, or from degeneration after axotomy, or in experimental neurodegenerative disease (Mitsumoto et al., 1994) . Most known BDNF functions are signalled via the full-length gp145 tyrosine kinase receptor (trk) B (Bothwell, 1995) ; intriguingly, it is found in neurones in the immediate vicinity of multiple sclerosis plaques as well as in reactive astrocytes in multiple sclerosis lesions (Stadelmann et al., 2002) . Therefore, T-cell-derived BDNF could directly act on target cells expressing the appropriate trkB receptor.
BDNF has been immunolocalized in in¯ammatory cells in active multiple sclerosis lesions (Stadelmann et al., 2002) . This indicates that, even in untreated multiple sclerosis patients, in¯ammatory cells might have a bene®cial (neuroprotective) effect in addition to their (probably major) detrimental role (Hohlfeld et al., 2000) . Indeed, the concept of`neuroprotective autoimmunity' has attracted considerable attention and is supported by experimental evidence from various animal models (Kipnis et al., 2000; Schori et al., 2001; Schwartz, 2001) . It is conceivable that there is a complex interplay between detrimental and bene®cial factors, and mediators in the in¯ammatory milieu of multiple sclerosis lesions. BDNF imported by GA-reactive T cells might help tip the balance in favour of the bene®cial, neuroprotective in¯uences. Indeed, in a rat neurodegenerative model, Kipnis and colleagues showed that rat immune cells stimulated by immunization with GA secreted neurotrophic factors upon restimulation with GA (Kipnis et al., 2000) .
The following scenario would accommodate both the ®ndings in experimental autoimmune encephalomyelitis and the observations in human multiple sclerosis. GA-speci®c activated T cells can pass through the blood-brain barrier. Inside the CNS, some GA-speci®c T cells cross-react with products of local myelin turnover presented by local APCs. In our previous studies, 8±15% of GA-reactive TCLs crossreacted with MBP as indicated by cytokine secretion, but not proliferation (Neuhaus et al., 2000) . Recognition of crossreactive antigens at the lesion site seems to be necessary for reactivation of the protective T cells and for their neuroprotective effect. In rat models, only MBP-and GA-speci®c, but not ovalbumin-speci®c, T cells confer neuroprotection (Moalem et al., 1999) . After reactivation in situ, GA-speci®c TH2-like regulatory T cells would not only provide antiin¯ammatory cytokines like IL-4, IL-5, IL-13, and transforming growth factor (TGF)-b, but also BDNF. Furthermore, TH1-like GA-reactive T cells, which are reduced but still present in GA-treated patients (Neuhaus et al., 2000; Farina et al., 2001) , would also have the capacity to release BDNF in multiple sclerosis lesions.
Implications for therapy with other altered peptide ligands
The above concept may be extended to other types of immunomodulatory therapy, especially with`altered peptide ligands' (APLs). By de®nition, they are derived from immunogenic peptide antigens by the selective alteration of one or more T-cell receptor-contacting residues. A good example is an APL designed from the myelin basic protein peptide 83±99 (Bielekova et al., 2000; Genain and Zamvil, 2000; Kappos et al., 2000) . This APL has been tested in clinical trials in multiple sclerosis patients. Despite several adverse effects, there was some evidence for partial ef®cacy and for a TH1-to-TH2 shift during treatment with low doses of the APL (Bielekova et al., 2000; Crowe et al., 2000; Kappos et al., 2000) . The rationales for APL and GA treatment are very similar: APLs are able to expand populations of TH0 and TH2 cells that have speci®city for the APL itself, but they can also cross-react with the native peptide. Thus, T cells speci®c for an APL analogue of myelin antigen will be able to penetrate the CNS, where they can down-regulate encephalitogenic in¯ammatory cells via`bystander suppression' (Steinman, 1996; Hohlfeld, 1997; Nicholson et al., 1997; Genain and Zamvil, 2000) . It should be noted, however, that TH2 responses can in principle contribute to myelin damage (Genain et al., 1996) .
Extrapolating from our present results to APL therapies in general, we would expect that APL-speci®c TH2 and TH1 cells are also capable of producing BDNF (as do GA-speci®c TH2 and TH1 cells). However, for APL therapy to work, it is obviously crucial that neither the TH1 nor the TH2 anti-APL response be encephalitogenic. An ideal APL would induce a non-encephalitogenic TH2 response that mediates local bystander suppression and neuroprotection. If both conditions were met, the TH1 cells could contribute to the therapeutic effect by acting as innocent carriers of neurotrophic factors.
